Regenerative Element and Reding Pharmaceuticals develop REGN1979 (CD20xCD3 bispecific antibody) for the treatment of non-Hodgkin's lymphoma

Regeneron and Zai Lab announced a strategic partnership to develop and commercialize REGN1979 (CD20xCD3 dual-specific antibodies) in Chinese mainland, Hong Kong, Taiwan and MacauThis partnership will support REGN1979 phase 2 clinical treatment for B-cell non-Hodgkin's lymphoma (B-NHL)REGN1979 is a new type of bispecific monoclonal antibody developed using the Regeneron bispecific antibody platform designed to kill tumors by connecting cytotoxic T cells (in combination with CD3) to lymphoma cells (in combination with CD20)under the terms of the agreement, Regeneron will receive an advance payment of $30 million and be eligible for additional regulatory and sales milestones of up to $160 millionIn some trials, Zai Lab will cover the global development costs of REGN1979 and will be granted the right to develop and exclusively commercialize REGN1979 oncology in Chinese mainland, Hong Kong, Taiwan and MacauREGN1979 was designated by the U.SFood and Drug Administration (FDA) for the treatment of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)REGN1979 is currently undergoing a Phase 1 trial and a potential Phase 2 trial for the treatment of FL, DLBCL and other advanced lymphomas